Estrogens, Esterified

Dosage for Estrogens, Esterified must be individualized to the lowest effective dose that controls symptoms for the shortest duration possible, consistent with treatment goals and risks for the individual woman.

• For Vasomotor Symptoms and Atrophic Vaginitis: The typical starting dose is 0.3 mg to 1.25 mg daily. Healthcare providers often recommend a cyclic regimen (e.g., 3 weeks on the medication followed by 1 week off) to mimic a natural hormonal cycle, although continuous daily dosing is also common.
• For Female Hypogonadism: The dosage is usually 2.5 mg to 7.5 mg daily, administered in divided doses for 20 days, followed by a 10-day rest period. If bleeding does not occur by the end of this period, the cycle is repeated.
• For Female Castration or Primary Ovarian Failure: A dose of 1.25 mg daily is common, often administered cyclically.
• For Prostatic Cancer (Palliative): Higher doses are required, typically 1.25 mg to 2.5 mg three times daily.
• For Breast Cancer (Palliative): The standard dose is 10 mg three times daily for at least three months.

Estrogens, Esterified is generally not indicated for use in children. Its use in the pediatric population is limited to rare cases of female hypogonadism or delayed puberty under the strict supervision of a pediatric endocrinologist. Safety and effectiveness in children have not been established for other indications. Estrogens can induce premature closure of the epiphyses (growth plates), potentially leading to permanent short stature if used before bone growth is complete.

Renal Impairment

There are no specific dosage adjustment guidelines provided by the manufacturer for patients with renal impairment. However, since estrogen metabolites are excreted by the kidneys, patients with severe renal disease should be monitored closely for potential accumulation of the drug.

Hepatic Impairment

Estrogens, Esterified is contraindicated in patients with known or suspected hepatic (liver) impairment or disease. The liver is the primary site of estrogen metabolism; impaired function can lead to dangerously high levels of circulating hormones and increased risk of toxicity.

Elderly Patients

Clinical studies (such as the Women’s Health Initiative) have suggested that women over the age of 65 may have an increased risk of developing probable dementia when treated with estrogens. Healthcare providers typically use extreme caution and the lowest possible doses in this population.

• Administration: Tablets should be taken orally. They can be taken with or without food. If the medication causes stomach upset, taking it with a meal or a snack may help.
• Consistency: Take the medication at the same time each day to maintain steady hormone levels in your bloodstream.
• Swallowing: Tablets should be swallowed whole with a full glass of water. Do not crush or chew the tablets unless specifically instructed by your pharmacist.
• Storage: Store at room temperature (20°C to 25°C or 68°F to 77°F), away from excessive heat, moisture, and direct light.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not double the dose to catch up, as this can increase the risk of side effects like nausea or breast tenderness.

Symptoms of an estrogen overdose may include severe nausea, vomiting, and withdrawal bleeding in females. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. While acute overdosage is rarely life-threatening, it may require supportive care.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop taking the medication without medical guidance, as sudden discontinuation can cause a return of symptoms.

Many patients taking Estrogens, Esterified experience mild side effects as their bodies adjust to the hormone levels. The most frequently reported include:

• Breast Tenderness or Enlargement: This is often one of the first signs of estrogen activity and may diminish over time.
• Headache: Mild to moderate headaches or migraines may occur or worsen in some patients.
• Nausea and Vomiting: Gastrointestinal upset is common, particularly when starting therapy.
• Abdominal Cramps and Bloating: Fluid retention in the abdominal area can cause discomfort.
• Changes in Vaginal Bleeding: This includes breakthrough bleeding, spotting, or changes in the amount of menstrual flow.

• Weight Changes: Some patients report weight gain or loss due to changes in fluid retention or appetite.
• Mood Swings: Increased irritability, anxiety, or symptoms of depression.
• Skin Changes: Development of melasma or chloasma (tan or brown patches on the face), which may persist even after the drug is stopped.
• Hair Loss: Thinning of scalp hair or, conversely, hirsutism (excessive hair growth in other areas).
• Vaginal Candidiasis: An increase in yeast infections due to changes in the vaginal environment.

• Gallbladder Disease: Estrogens can increase the concentration of cholesterol in bile, leading to gallstones.
• Intolerance to Contact Lenses: Changes in the curvature of the cornea may make contact lenses uncomfortable.
• Hypercalcemia: In patients with breast cancer and bone metastases, estrogens may cause dangerously high calcium levels in the blood.
• Pancreatitis: Rare cases have been reported, usually in patients with pre-existing high triglyceride levels.

> Warning: Stop taking Estrogens, Esterified and call your doctor immediately if you experience any of these serious symptoms:

• Signs of a Blood Clot (VTE): Sudden shortness of breath, chest pain, coughing up blood, or pain, swelling, and redness in one leg (Deep Vein Thrombosis).
• Signs of a Stroke: Sudden numbness or weakness (especially on one side of the body), severe headache, slurred speech, or vision changes.
• Signs of a Heart Attack: Chest pressure, squeezing, or pain that radiates to the jaw or shoulder, accompanied by sweating and nausea.
• Liver Problems: Yellowing of the skin or eyes (jaundice), dark urine, or severe upper abdominal pain.
• Lumps in the Breast: Any new breast mass or unusual nipple discharge should be evaluated for breast cancer.
• Severe Allergic Reaction: Hives, difficulty breathing, or swelling of the face, lips, and throat.

Prolonged use of Estrogens, Esterified is associated with several long-term risks. The most significant is the increased risk of endometrial hyperplasia (overgrowth of the uterine lining) and endometrial cancer in women with an intact uterus. To mitigate this, a progestogen is usually prescribed alongside estrogen. Long-term use (typically more than 5 years) is also linked to a slightly increased risk of breast cancer and a potential increase in the risk of dementia in women over 65.

Estrogens, Esterified carries several FDA Black Box Warnings, the highest level of caution:

1. 1Endometrial Cancer: There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (estrogen without progestogen).
2. 2Cardiovascular Disorders: Estrogens should not be used for the prevention of cardiovascular disease. The WHI study reported increased risks of stroke and deep vein thrombosis (DVT).
3. 3Breast Cancer: The WHI study also reported increased risks of invasive breast cancer in women taking estrogen plus progestin combinations.
4. 4Dementia: The WHI Memory Study reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older.

Report any unusual symptoms to your healthcare provider immediately to ensure your treatment remains safe and effective.

Estrogens, Esterified is a potent hormonal therapy that requires careful medical supervision. It is not a "one size fits all" medication. Before starting therapy, patients must undergo a complete physical examination, including a pelvic exam and a Pap smear, as well as a clinical breast examination and mammography. Therapy should be re-evaluated at least every 3 to 6 months to determine if it is still necessary.

The FDA has issued several Black Box Warnings for Estrogens, Esterified. These include the risk of Endometrial Cancer in women with a uterus who take estrogen without a progestin. Additionally, the medication is linked to an increased risk of Stroke, Deep Vein Thrombosis (DVT), and Pulmonary Embolism. It should not be used to prevent heart disease or dementia, as studies have shown it may actually increase the risk of these conditions in certain populations.

• Allergic Reactions: While rare, some patients may experience anaphylaxis or angioedema. If you have a history of severe allergies to estrogen products, you must not take this medication.
• Fluid Retention: Estrogens can cause significant fluid retention. Patients with conditions that might be exacerbated by this, such as asthma, epilepsy, migraines, or cardiac/renal dysfunction, require close monitoring.
• Gallbladder Disease: There is a 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens.
• Visual Abnormalities: Discontinue medication immediately if there is a sudden partial or complete loss of vision, or a sudden onset of proptosis (bulging eyes), diplopia (double vision), or migraine.
• Hypertriglyceridemia: In patients with pre-existing high triglycerides, estrogen therapy may lead to massive elevations of plasma triglycerides leading to pancreatitis.

Patients on Estrogens, Esterified should have the following monitored regularly:

• Blood Pressure: Estrogens can cause an increase in blood pressure in some women.
• Lipid Profile: Monitoring of cholesterol and triglycerides, especially in those with baseline elevations.
• Mammograms: Annual or biennial screenings as recommended by your doctor.
• Thyroid Function: Estrogens increase thyroid-binding globulin (TBG); patients on thyroid replacement therapy may need their dose adjusted.
• Liver Function Tests: Periodic checks if there is a history of liver issues.

Estrogens, Esterified generally does not interfere with the ability to drive or operate machinery. However, if you experience side effects like dizziness, severe headaches, or vision changes, you should avoid these activities until the symptoms resolve and you have consulted your doctor.

Alcohol consumption can increase the levels of circulating estrogen in the body. Chronic heavy drinking may increase the risk of side effects and potentially increase the risk of breast cancer associated with estrogen therapy. It is generally advised to limit alcohol intake while on HRT.

Do not stop taking Estrogens, Esterified abruptly without consulting your doctor. Sudden discontinuation can lead to a rapid return of vasomotor symptoms (hot flashes). If you wish to stop therapy, your healthcare provider will likely suggest a tapering schedule to allow your body to adjust to the lower hormone levels.

> Important: Discuss all your medical conditions, including any history of blood clots, cancer, or liver disease, with your healthcare provider before starting Estrogens, Esterified.

Certain medications should never be combined with Estrogens, Esterified due to the risk of severe adverse reactions:

• Aromatase Inhibitors (e.g., Anastrozole, Letrozole): Estrogens can interfere with the pharmacological action of these drugs, which are used to treat breast cancer by lowering estrogen levels. Taking them together renders the cancer treatment ineffective.
• Tranexamic Acid: Combining estrogens with this anti-fibrinolytic medication significantly increases the risk of serious blood clots (thrombosis).

• CYP3A4 Inducers (e.g., Rifampin, Phenytoin, Carbamazepine, Phenobarbital): These medications speed up the metabolism of estrogen in the liver, which can significantly decrease the levels of Estrogens, Esterified in your blood, leading to a return of symptoms or breakthrough bleeding.
• CYP3A4 Inhibitors (e.g., Erythromycin, Clarithromycin, Ketoconazole, Itraconazole): These drugs slow down the metabolism of estrogen, potentially leading to dangerously high levels of the hormone and increasing the risk of side effects like blood clots.
• Thyroid Hormones: Estrogens increase the level of Thyroid-Binding Globulin (TBG). Patients with hypothyroidism who are taking Levothyroxine may need an increase in their thyroid dose when starting estrogen therapy to maintain adequate free thyroid hormone levels.

• Anticoagulants (e.g., Warfarin): Estrogens can decrease the effectiveness of blood thinners, requiring more frequent monitoring of the INR (International Normalized Ratio).
• Corticosteroids: Estrogens may increase the effects and toxicity of corticosteroids by slowing their clearance from the body.
• Diabetes Medications: Estrogens can occasionally impair glucose tolerance. Patients with diabetes may need to adjust their insulin or oral hypoglycemic dosages.

• Grapefruit Juice: Grapefruit is a known inhibitor of the CYP3A4 enzyme. Consuming grapefruit or its juice while taking Estrogens, Esterified can lead to increased blood levels of the drug, raising the risk of side effects.
• High-Fat Meals: While not strictly contraindicated, very high-fat meals might slightly alter the rate of absorption, though the clinical significance is usually minimal.

• St. John's Wort: This herbal supplement is a potent inducer of liver enzymes (CYP3A4) and can significantly lower the effectiveness of Estrogens, Esterified, potentially causing breakthrough bleeding or a return of hot flashes.
• Soy Isoflavones: Since soy contains phytoestrogens, taking high-dose soy supplements alongside esterified estrogens may result in excessive estrogenic activity. Use caution and consult your doctor.

Estrogens, Esterified can interfere with several laboratory tests, including:

• Prothrombin Time (PT): May be accelerated due to increased levels of clotting factors.
• Metyrapone Test: Reduced response may occur.
• Glucose Tolerance Test: May be impaired.
• Serum Folate: Estrogens may decrease serum folate concentrations.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as they can significantly impact how Estrogens, Esterified works in your body.

Estrogens, Esterified must NEVER be used in patients with the following conditions:

1. 1Undiagnosed Abnormal Genital Bleeding: Any unexplained vaginal bleeding must be investigated to rule out malignancy before starting estrogen therapy.
2. 2Known or Suspected Pregnancy: Estrogens can cause fetal harm and are strictly contraindicated during pregnancy.
3. 3History of Thromboembolic Disease: This includes a history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), stroke, or myocardial infarction (heart attack).
4. 4Known or Suspected Estrogen-Dependent Neoplasia: This includes breast cancer or endometrial cancer. Estrogens can stimulate the growth of these tumors.
5. 5Active Liver Disease: Patients with impaired liver function cannot metabolize estrogens properly, leading to toxic accumulation.
6. 6Known Anaphylaxis or Angioedema: A history of severe hypersensitivity to any component of the formulation.

Conditions requiring careful risk-benefit analysis and close monitoring include:

• Family History of Breast Cancer: Especially in first-degree relatives.
• Endometriosis: Estrogens may exacerbate this condition or lead to malignant transformation of residual endometrial implants.
• Uterine Leiomyomata (Fibroids): Estrogens may cause fibroids to increase in size.
• Hypertriglyceridemia: Risk of estrogen-induced pancreatitis.
• Hypocalcemia: Use with caution in patients with severe hypocalcemia.

Patients who have had allergic reactions to other estrogen products (like conjugated estrogens or estradiol patches) should be extremely cautious. While the source of the estrogen may differ (equine vs. plant-derived), the molecular structure of the active metabolites is similar, and cross-sensitivity is highly likely.

> Important: Your healthcare provider will evaluate your complete medical history, including family history and lifestyle factors, before prescribing Estrogens, Esterified.

Estrogens, Esterified is classified as FDA Pregnancy Category X. There is no appropriate indication for estrogen therapy during pregnancy. Estrogens can cause significant harm to a developing fetus, including urogenital abnormalities. If a patient becomes pregnant while taking this medication, it must be discontinued immediately. It is not used in fertility treatments and should not be used to prevent miscarriage.

Estrogen administration to nursing mothers has been shown to decrease the quantity and quality of breast milk. Furthermore, detectable amounts of estrogens have been identified in the milk of mothers receiving the drug. Because of the potential for adverse effects in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Safety and effectiveness in pediatric patients have not been established except for certain cases of delayed puberty or hypogonadism. Estrogens can cause premature closure of the growth plates (epiphyses) in children, which can lead to permanent short stature. Use in children must be managed by a specialist and monitored with regular bone-age assessments.

Data from the Women's Health Initiative (WHI) suggest an increased risk of stroke and probable dementia in women over 65 years of age. There is insufficient evidence to determine whether the risks differ for women over 75. Healthcare providers generally avoid starting HRT in women who are many years past the onset of menopause due to the increased cardiovascular risks.

In patients with impaired renal function, the metabolites of esterified estrogens may accumulate in the body. While no specific dose adjustments are mandated, clinicians should monitor these patients for signs of estrogen excess, such as severe breast tenderness or fluid retention.

Estrogens, Esterified is contraindicated in patients with active or chronic liver disease. The liver's inability to conjugate and metabolize estrogens leads to elevated plasma levels, which significantly increases the risk of serious adverse events, including blood clots and liver tumors (adenomas).

> Important: Special populations require individualized medical assessment and frequent monitoring to ensure the safety of hormone replacement therapy.

Estrogens, Esterified acts by binding to nuclear Estrogen Receptors (ERα and ERβ) in target tissues. These receptors are ligand-activated transcription factors. Once the estrogen molecule binds, the receptor undergoes a conformational change, dimerizes, and translocates to the nucleus where it binds to Estrogen Response Elements (EREs) on the DNA. This interaction regulates the expression of genes involved in the cell cycle, protein synthesis, and lipid metabolism. In the hypothalamus, it provides negative feedback to reduce the secretion of Gonadotropin-Releasing Hormone (GnRH), which in turn reduces the surge of Luteinizing Hormone (LH) responsible for hot flashes.

• Dose-Response: There is a clear dose-response relationship between estrogen levels and the relief of vasomotor symptoms. Higher doses provide greater relief but carry higher risks of endometrial hyperplasia.
• Onset: Relief of hot flashes may begin within a few days, but the full therapeutic effect often takes 4 to 8 weeks.
• Tolerance: Tolerance to the therapeutic effects does not typically develop, but the body's requirement for estrogen naturally decreases as it adjusts to the postmenopausal state.

| Parameter | Value |

|---|---|

| Bioavailability | ~10% (due to high first-pass metabolism) |

| Protein Binding | 80% - 98% (Albumin and SHBG) |

| Half-life | 10 - 20 hours (Metabolites) |

| Tmax | 4 - 6 hours |

| Metabolism | Hepatic (CYP3A4) |

| Excretion | Renal (primarily as conjugates) |

• Molecular Components: Primarily Sodium Estrone Sulfate (C18H21NaO5S) and Sodium Equilin Sulfate (C18H19NaO5S).
• Solubility: Soluble in water and alcohol.
• Structure: These are steroid-based molecules with a sulfate group attached at the C3 position, which makes them water-soluble "esterified" salts.

Estrogens, Esterified is classified as an Estrogen [EPC]. It is part of the broader category of Hormone Replacement Therapy (HRT) medications. Related medications include Conjugated Estrogens (equine-derived), Estradiol (bioidentical), and Estropipate.